和铂医药：将更新与深化推进其与阿斯利康的全球战略合作

Core Insights - The announcement highlights the deepening global strategic collaboration between Heptares Therapeutics and AstraZeneca established in March 2025 [1] - The partnership focuses on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) [1] Collaboration Details - AstraZeneca will nominate research projects to Heptares Therapeutics annually over the next four years, demonstrating the ongoing commitment to the partnership [1] - Heptares Therapeutics is eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of licensed projects [1]